Top Stories News

Recent breakthroughs show that China is emerging as a world leader in stem-cell research and development, says Emerging Healthcare Solutions President and CEO Cindy Morrissey.

Arena Pharmaceuticals and its partners at Eisai have had a chance to review exactly what the FDA wants to see on their experimental weight drug.

Some Johnson & Johnson ($JNJ) investors have resorted to court action, saying that directors and executives not only ignored 'red flags' that something was rotten within J&J, but allowed the company's once-stellar reputation to be destroyed.

Novartis latest product, the multiple sclerosis treatment Gilenya, has already been hailed as a prospective blockbuster.

For the second time in two months, we're seeing reports that Chinese officials are planning to lower drug prices.

Novartis' pledged to invest $500 million in Russian manufacturing, R&D and public health.

According to a new report, drugmakers defraud the federal government more than any other business.

Roche confirmed that following the reviews of Avastin (bevacizumab) in metastatic breast cancer by EMA) and FDA, the following regulatory announcements were made by the individual health authorities.

GE Healthcare today announced the expiration of the initial offering period of the previously announced tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc..

Indian drugmakers are aiming to team up with China in a bid to outpace western drugmakers who've been scrambling to grab market share in both countries.

The outgoing chief of the European Medicines Agency concluded that the $85 billion the industry spends on drug R&D each year is simply wasted.

GlaxoSmithKline is splashing out UKpound162m on a protein drinks maker, but signalled that a lack of cheap takeover deals could see the drugs giant re-start its multi-billion pound share-buyback programme.

A recent analysis published by THE SAGE GROUP concluded that 3 million people in Western Europe have critical limb ischemia (CLI).

Bayer HealthCare is building a new facility center in Wuppertal on an area of some 1,000 square meters for the biotechnological production of pharmaceuticals to be used in clinical trials.

Illegal online drug sellers have provided tens of millions of Americans prescription medication via the Internet without a valid prescription, recent research has found.

New data shows that Xgeva (denosumab) delayed the spread of prostate cancer into bone, and that's set the oncology world abuzz.

Negotiators say India will withdraw its complaint filed at the World Trade Organization, now that it has reached an agreement with E.U. trade police.

Genzyme Corp. today reiterated the unanimous recommendation of its board of directors.

Sanofi-Aventis' ($SNY) lowball bid for Genzyme ($GENZ) is set to expire at midnight tonight.

The BioIndustry Association welcomes the publication today of the latest government statistics highlighting the growth of the UK's innovative bioscience sector.

Russia has been rumbling at global pharma for awhile, but Prime Minister Vladimir Putin has sharpened his warnings to foreign drugmakers.

Pharma M&A is up by 20 percent so far this year as drugmakers scramble to refill depleted pipelines, push into emerging markets and diversify beyond prescription drugs.

In what is likely to prove a shocker for many FDA watchers, the agency's expert advisors voted 13 to 7 in favor of approving Orexigen's obesity drug Contrave.

Merck KGaA is supporting the World Health Organization (WHO) in the fight against the neglected tropical disease schistosomiasis.

The Bayer Group aims to invest its resources as a whole more consistently in growth and innovation capability. 'We have a very successful record in innovation,' Management Board Chairman Dr. Marijn Dekkers said.

China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca.

Focus on cancer vaccines, auto-immune disease diagnostics and treatment

As time runs down on Sanofi-Aventis' $69-per-share offer for Genzyme --the offer expires Dec. 10--both sides are still far apart on an agreement.

The steady drumbeat of downbeat manufacturing news and recalls has heightened worries among market-watchers.

Genzyme Corporation has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash.

Bristol-Myers Squibb Company and Alvin Ailey American Dance Theater announced the launch of the 2011 REYATAZ? (atazanavir sulfate) 'Fight HIV Your Way' contest.

China is working on a step-by-step reduction in drug prices that previously had been excused from the government's controls.

The New England Journal of Medicine is weighing in on social media.

Merck KGaA announced that the U.S. Food and Drug Administration has extended its review period for Cladribine Tablets.

FDA extended the review to 'provide additional time for a full review of additional information provided under the new drug application.'

Abbott (NYSE: ABT) has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group.

Johnson & Johnson ($JNJ) execs should write a blues song about recalls.

Stelmi has created a technical centre at its headquarters near Paris, which will be operational early next year.

UK-based Honeyman Group will open a pharmaceutical training facility in February 2011.

The FDA has released its latest list of scarce drugs, and several cancer drugs are included.

Privacy advocates are asking the Federal Trade Commission to investigate how that information is used in drug marketing.

Roche is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals, according to the UK biotech.

Animal rights activists have claimed responsibility for sending a package of razor blades to a UCLA researcher involved in animal studies.

Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree.

UK biopharmaceutical firm Xention has raised ?8m in private equity funding to advance the development of drugs to treat atrial fibrillation.

WHO has said the little-used World Trade Organisation (WTO) licensing system for generic medicines during health emergencies may actually become useful.

Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September.

Half of Europeans using the Internet for health information are interested in online patient education programs from pharmaceutical companies.

Chris Brinsmead, chairman of AstraZeneca Pharmaceuticals UK, has become the UK government’s life sciences business adviser.

The National Lipid Association announced the recent acceptance of its journal for indexing in PubMed and MEDLINE by the U.S. National Library of Medicine.

Johnson & Johnson has been hit with another recall, but this time J&J wasn't the company overseeing production.

Roche singled out its work in RNAi when choosing its R&D targets for the budget axe, announcing plans to shutter the work underway in Kulmbach, Germany, Nutley, NJ and Madison, WI.

Despite rumors, GlaxoSmithKline's senior vice president of medicines discovery and development, says his company isn't considering a bid for Genzyme.

Approved as an osteoporosis treatment--sold under the brand name Prolia--the drug got the FDA nod for fracture prevention in certain cancer patients.

At CPHI Worldwide 2010, Cargill announced a new pharmaceutical patent application for Zerose? erythritol.

Attendees up by 14%,* Exhibitor Numbers Increase to 1934.

Shares of Human Genome Sciences had been trimmed 11 percent as investors fretted over the implications of an FDA staff analysis of its lupus drug Benlysta.

The U.S. FDA approved Halaven to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

For all the promise of tweaking the healthcare reform law in pharma-friendly ways, there's now a counterweight to those very plans.

Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight.

Roche has failed to get the cancer drug Avastin on the National Health Service formulary for colorectal-cancer treatment.

Bristol-Myers Squibb Foundation launches $100 million initiative targeting America's type 2 diabetes crisis.

Nycomed's strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pan...

Advaxis was awarded a Qualifying Therapeutic Discovery Project credit from the Federal Government for ADXS11-001.

Apparently, Novartis ($NVS) has done just that, using professional athletes as a draw at doctor dinners.

China Medicine Corporation today announced financial results for the third quarter ended September 30, 2010.

FDA Commissioner Margaret Hamburg is trying to forestall any talk of cutting her agency's funding.

Program to Provide Full Regulatory Support for Clients' Clinical Development Programs Under Experienced Leadership.

Sanofi-aventis has sent a letter to Genzyme Corporation requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9.

PhRMA still has its eyes on healthcare reform.In fact, PhRMA spent some big bucks to back candidates who supported healthcare reform the first time around.

The US Food and Drug Administration (FDA) approved KOMBIGLYZE? XR for the treatment of type 2 diabetes in adults.

Apricus Bio will use the proceeds of the grant funds to continue development of PrevOnco?, RayVa? and Femprox?.

Allergan is gearing up to promote Botox as a migraine-fighter, a newly approved use for the wrinkle-fighting, muscle-relaxing drug.

Chinese officials gave the go-ahead to Sanofi-Aventis' ($SNY) joint venture with Hangzhou Minsheng Pharmaceutical Group.

As healthcare and pharma experts are finding that the Washington power shift will present some new challenges.

Pfizer Inc. reported financial results for third-quarter 2010.

The U.S. Justice Department saying that unmodified DNA should not be patentable.

Waksal told that his new biotech company will be bigger and better than ImClone ever was.

This time driving a Pfizer recall of the cholesterol-fighting blockbuster Lipitor.

Drugmakers may be focusing on smaller deals this year, rather than the megamergers of 2009, but those smaller buys do add up.

The World Health Organisation (WHO) says four major medicine companies are backing an initiative to boost the flow of pharmaceuticals fighting lower profile tropical diseases.

UK pharmaceutical manufacturer GlaxoSmithKline (GSK) has licensed a treatment for Fabry disease from Amicus Therapeutics.

GlaxoSmithKline and its subsidiary SB Pharmco have agreed to pay $750 million to resolve criminal and civil allegations relating to the manufacturing and sale of certain adulterated drugs.

The government has set up an annual fund of ?200 million per year through 2014 to financerejected drugs .

Bristol-Myers Squibb officials promise that they're scrambling to fix 'significant' problems at a Puerto Rico plant.

Latest figures, released by MedTRACK, a biomedical database of Life Science Analytics, show stagnant product development across the Asia Pacific (APAC) region.

Some health conditions still have no treatments while the drugs invented to treat others are less effective than they might be. Dr Sarah Houlton describes the recent efforts of medicinal chemists to address these challenges.

Celgene has wrapped up its $3 billion-plus buyout of Abraxis BioScience.

The FDA's decision to reject Arena Pharmaceuticals' application for lorcaserin raises the stakes for two other companies looking for approval for their weight-loss drugs.

UK Science Minister David Willetts and Health Minister Lord Howe have launched an initiative to boost partnership between academics, clinicians and the life sciences industry.

The FDA finally approved Allergan wrinkle-fighter Botox as a treatment for migraines.

The Avandia mess weighed on GlaxoSmithKline's third-quarter earnings, that's now a matter of record.

Sanofi says that regulators have given the company a green light to proceed with its $18.5 billion buyout bid.

China has the advantages of scientific expertise and comprehensive infrastructure, which are critical for drug discovery activities.

BASF has lifted its profit outlook for the full year after reporting strong third-quarter sales.

Drugs for these chronic diseases present a novel set of challenges about how to assess their safety.

Last week, pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills.

A drug that could herald the ‘disappearance of warfarin clinics’ in the UK has won the 2010 UK Prix Galien Innovative Product Award.

PharmOptima, LLC, is pleased to announce the appointment of Rick Coulon as Director of business development.

We won't find out what happens to Merck's disputed Remicade rights until next year.

While Venture capital investments declined sharply in the third quarter of 2010, Biotechnology continued to bring in significant funding.

Forty-five countries took part in Operation Pangea III this month, which resulted in 76 people either being arrested or placed under investigation. In total 290 online pharmacies selling fake and illegal drugs were shut down.

Pfizer Inc.and King Pharmaceuticals have entered into a definitive merger agreement. Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share.

Some Genzyme investors aren't willing to wait and see if the Big Biotech's board can be gradually lured to the bargaining table by Sanofi's slow motion M&A tactics.

The FDA is far more likely to be influenced by a rejection than an approval.

The Chinese government appears to be stepping up its efforts to fight the contamination and fakery that have sullied its reputation as a drug supply source.

A report by an investigating committee finds that top Ministry officials made the call. The report states the decision to close the three plants.

Some big names have cropped up in a new round of emerging-markets investments.

UCB and Synosia Therapeutics announced today a new strategic partnership in neurology.

Novartis has agreed with the World Health Organization (WHO) to continue its efforts to eliminate leprosy.

Meriva has been elected 'Best New Product'of the year by the judging panel of the European Outsourcing Awards.

Sanofi-Aventis announced that it's restructuring its U.S. pharmaceutical operations.

The FDA Abbott Laboratories is voluntarily withdrawing Meridia from the U.S. market following concerns that the drug may increase risk of serious cardiovascular events in patients with heart problems. In addition, the company is pulling the drug from...

Genzyme's board officially nixed Sanofi-Aventis' hostile bid for the company.But the back-and-forth between the two companies is increasingly tense.

Pfizer has recalled 10 lots of the cholesterol drug, citing a 'musty odor' in some bottles of tablets made by a contract manufacturer.

Drug market of China is projected to grow 25 percent to 27 percent to more than $50 billion, to become the world's third-largest pharma market.

Indian regulators have been considering all sorts of measures to protect homegrown drugmakers,Understandably, international drugmakers don't like the idea.

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work

The juxtaposition of Sanofi-Aventis headlines today is telling.

A couple of juicy pharma cases are coming up at the Supreme Court, so Chief Justice John Roberts has unloaded his Pfizer stock and is now ready to take part.